-transparent.png){kind=logo}
A case report of amoxapine-induced tardive dyskinesia following discontinuation of amoxapine therapy is reported. During 68 weeks of therapy, the patient received a maximum of amoxapine 400 mg/d. Six months after amoxapine discontinuation, the patient continued to have symptoms of tardive dyskinesia. These symptoms correlate with the dopamine receptor-blocking property of amoxapine and its metabolites. We propose that amoxapine therapy be monitored for the long-term as well as the short-term adverse effects of dopamine receptor-blockade.
Related Publications
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
January 2009,
Indian journal of psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
August 1986,
The American journal of psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
March 1986,
The Journal of clinical psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
January 1986,
The Hillside journal of clinical psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
May 1984,
The American journal of psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
May 1996,
The American journal of psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
May 1996,
The American journal of psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
August 1999,
The American journal of psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
January 1998,
The Journal of clinical psychiatry,
G K Tao, and
D T Harada, and
M E Kootsikas, and
M N Gordon, and
J H Brinkman
January 2017,
Indian journal of psychological medicine,
